Original paper

Differential expression of long noncoding RNA in hepatocellular carcinoma on top of chronic HCV and HBV infections

Hany S. Sabry¹, Safaa I. Tayel², Mohamed E. Enar³, Naglaa S. Elabd¹

¹Tropical Medicine Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt
²Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt
³Al Mahala Elkobra Fever Hospital, Gharbia, Egypt

Abstract

Aim of the study: The task of long noncoding RNAs (lncRNAs) as a prospective goal for hepatocellular carcinoma (HCC) is a candidate for research. Several lncRNAs are involved in signal transduction, directing gene expression and epigenetic alteration in normal and cancer cells. Dysregulation of diverse lncRNAs has been involved in the pathogenesis and progression of different cancers including HCC. We aimed to investigate the differential expression of lncRNAs (aHIF, hPVT1, ANRIL) in HCC on top of chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infections.

Material and methods: 182 participants were included: 85 patients with HCC in addition to 50 patients with cirrhosis on top of chronic HCV or HBV, and 47 healthy subjects as controls. HCC was diagnosed by triphasic computed tomography (CT). Detection of α-fetoprotein (AFP) and serological markers of HCVAb and HBsAg by enzyme-linked fluorescent immunoassay (ELFA) and quantitation of lncRNAs by real time PCR were applied.

Results: Upregulation of ANRIL and hPVT1 and downregulation of aHIF were observed in patients with HCC on top of HCV and HBV vs. controls. Circulating aHIF could be of major diagnostic importance to discriminate HCC on top of HCV from cirrhotic patients with sensitivity 86.67% and specificity 91.89% whereas circulating hPVT1 had sensitivity 85.0% and specificity 84.62%; moreover ANRIL had AUC 0.902 and could discriminate HCC on top of HBV from cirrhotic patients.

Conclusions: The differential expression of lncRNAs (ANRIL, hPVT1 and aHIF) might be of major worth in predicting the occurrence of HCC in cirrhotic patients related to chronic viral hepatitis and could be beneficial in the early management.

Key words: hepatocellular carcinoma, HBV, HCV, lncRNAs.

Address for correspondence

Dr. Safaa I. Tayel, Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Menoufia University, Egypt, e-mail: drsafaa_tayel@yahoo.com

Introduction

Hepatocellular carcinoma (HCC) is considered as one of the most common malignant tumors as well as an ecumenical health concern [1]. Parallel to several other tumors, HCC is recognized by the involvement of several gene networks in addition to imbalance of many signaling pathways [2, 3]. Protein-coding genes and noncoding RNA (ncRNA) genes are involved in these genetic dysregulations [4]. Although the former was the research subject, the latter (ncRNA) has recently been realized to play a part in the pathological processes involved in HCC development. It is noteworthy that the great plurality of the human genome is transcribed into ncRNA, whereas 2% or less of the genome encodes proteins directly [5].
Functional RNA that is not translated into protein is called ncRNA. ncRNAs include ribosomal RNA (rRNA), transfer RNA (tRNA), and small nuclear ribonucleic acids (snRNA) that process pre-mRNA, piwi-interacting RNA (piRNA), long noncoding RNA (lncRNA), microRNA (miRNA), etc. [6]. The ability to perform biological functions at the gene expression level is a common characteristic feature of these RNAs [7].

Plentiful ncRNAs were described as functional molecules that have a crucial function in different biological processes and pathological conditions through the advances in high-throughput sequencing technology [8]. lncRNAs and miRNA organize different pathological processes, such as tumor occurrence [9]. Some essential ncRNAs have been recognized to participate in the pathophysiology of the disease in the scope of HCC [10].

Hypoxia-inducible factors (HIFs) are identified as essential transcriptional regulators which are activated during hypoxia [11]. The study on HIFs is currently concentrated on two main manifestations, the transcriptional regulation mechanism of HIFs as well as the cancer therapy that targets HIFs [12].

Plasmacytoma variant translocation 1 (PVT1) is one of the lncRNA class that is encoded by the PVT1 gene (also recognized as the Pvt1 oncogene). PVT1 functions as an oncogene that participates in multiple cancers phenotype [13].

Antisense non-coding RNA in the INK4 locus (ANRIL) is a lncRNA that consists of 19 exons, spanning 126.3 kb in the genome [14]. It binds to CBX7 (Chromebox 7) in the polycomb repressive complex 1 and to SUZ12, a component of polycomb repression complex 2 and via these interactions has been implicated in transcriptional repression. ANRIL-mediated recruitment of these complexes alters the shape of epigenetic chromatin and, hence, in a cis-acting manner it suppresses the expression of such a gene cluster [15]. Thus, in this study we aimed to estimate the differential expression of lncRNA (aHIF, hPVT1, and ANRIL) in HCC on top of chronic HCV and HBV infections and determine whether lncRNAs were selectively dysregulated according to viral etiology, and furthermore we studied their associations with clinical criteria.

Material and methods

Subjects

This study was carried out in the Tropical Medicine Department in collaboration with the Medical Biochemistry and Molecular Biology Department, Faculty of Medicine. This study included one hundred and eighty-two participants. They were selected from the Tropical Medicine Department between April 2017 and December 2019. Participants were categorized into four groups: group A included 45 HCC patients with chronic HCV infection, group B was composed of forty HCC patients with chronic HBV infection, group C included 50 patients with liver cirrhosis on top of chronic viral hepatitis: HCV (37 patients) or HBV (15 patients), and group D comprised 47 apparently healthy subjects who were HBV and HCV negative and of matched age and gender as controls. HBV and HCV infections were identified by detecting HCVAb or HBsAg that was established by real-time polymerase chain reaction (PCR).

For all subjects, history, clinical evaluation, laboratory investigations and abdomino-pelvic ultrasonography were done. Patients with HCC or liver cirrhosis not related to chronic HBV or HCV were excluded from the study in addition to previously treated HCC patients and patients with malignant disease elsewhere in the body. Hepatocellular carcinoma detected in ultrasound evaluation was confirmed by characteristic features in triphasic computed tomography (CT) (wash out lesions). HCC patients were exposed to baseline computed tomography of the chest, abdomen and pelvis and bone scan for valuation of distant metastases.

Ethical approval: This study was performed under the direction of the Helsinki Declaration. All participants gave informed consent assured by the Faculty of Medicine, Menoufia University ethical committee.

Methods

Blood sampling

All subjects in this study donated 10 ml venous blood samples. Five milliliters of fresh blood were used for estimation of the following: Two milliliters of fresh blood were placed in ethylene diamine tetra-acetic acid (EDTA)-containing tubes and were used for a complete blood count (CBC) by Sysmex XN-1000 (Japan, 19723, B.M Egypt company). One milliliter of fresh blood was gathered in a citrate tube for PT and INR measurement (BIOMED – LiQUIPLASTIN diagnostic kit, Germany). Two milliliters of fresh blood were placed in EDTA-containing tubes, then centrifuged at 4000 rpm for 10 min for separation of plasma that was further used for lncRNA extraction and quantification by real-time PCR.

Serum was isolated from the remaining 5 ml of blood in a plain tube, left to coagulate for 30 min, then centrifuged at 4000 rpm for 10 min; for further investigation of liver function tests including serum alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST) by the kinetic UV-optimized method IFCC LTEC Kit (England), serum albumin by employing a quantitative method of enhanced specificity, the bromocresol green colorimetric method, by a Diamond Diagnostics Kit (Germany), total and direct bilirubin was assayed by a Diamond Diagnostics Kit (Germany), serum creatinine by standard colorimetric tests utilizing a Diamond Diagnostics Kit (Germany), serum urea by Mod Berthelot enzymatic colorimetric method using a Diamond Diagnostics Kit (Germany). Detection of α-fetoprotein (AFP) and serological markers of HCV Ab and HBsAg was performed by enzyme-linked fluorescent immunoassay (ELFA) utilizing miniVIDAS systems (bioMerieux, Marcy l’Etoile, France); positive tests were assured by real-time PCR to give precise quantitation of HCV RNA and HBV DNA.

Detection and quantitation of lncRNAs by real-time PCR

First the lncRNAs were extracted from plasma samples using a miRNeasy Mini Kit (cat. no. 217004, Qiagen, Germany) that syndicates phenol/guanidine-based samples’ lysis with silica-membrane-based purification of RNA. Secondly, reverse transcription (RT) of RNA into cDNA by high capacity cDNA Reverse Transcription Kits supplied by Thermo Fisher Scientific, Applied Biosystem, was performed. Then 20 μl of cDNA RT reaction mixture was prepared as follows: 10 μl of RNA sample and 10 μl of 2x RT master mix (that includes 2 μl of 10X RT buffer, 0.8 μl of 25X DNTP Mix (100 mM), 2 μl of 10X RT random primers, 1 μl of MultiScribe reverse transcriptase, 1 μl of RNase inhibitor and 3.2 μl of nuclease free water). The thermal cycler (2720 Singapore) was programmed in these conditions: 25°C for 10 min, 37°C for 120 min, 85°C for 5 min and hold at 4°C. Finally, the quantitative step of lncRNAs including: ANRIL, aHIF and hPVT1 was performed using a real-time PCR instrument (Applied Biosystems 7500 thermal cycler, Foster City, USA) using primers supplied by Thermo Fisher Scientific, Invitrogen, USA, as follows: ANRIL: Forward 5’ CAACATCCACCTGATCTTAACA 3’, Reverse 5’ AGCTTCGTATCCCCAATGAGATACA 3’, aHIF: Forward 5’ TTTGTGTTTGAGCATTTTAATAGGC 3’, Reverse 5’ CCAGGCCCCCTTTGACAGCTG 3’, hPVT1: Forward 5’ AAAACGGCAGCAGGAAATGT 3’, Reverse 5’ ATTCCCATAGAAGGGGCAGG 3’. lncRNA expression was normalized by using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a reference gene: Forward 5’ CTCTGCTCCTCCTGTTCGAC 3’, Reverse 5’ TTAAAAGCAGCCCTGGTGAC 3’.

The total volume of the PCR reaction mix for each sample was calculated as 20 μl that contains 10 μl of

![Fig. 1. A) Amplification plot curve for relative quantitation (RQ), of ANRIL, B) amplification plot curve for RQ of aHIF, C) amplification plot curve for RQ of hPVT1, D) Melting curve analysis for ANRIL, E) melting curve analysis for aHIF, F) melting curve analysis for hPVT1](image-url)
SYBR green master mix with low ROX dye (Thermo Fisher Scientific, Applied Biosystem), 1 μl of forward primer of both target and reference gene and 1 μl of reverse primer of both target and reference, 3 μl of cDNA (RT) product and 5 μl of nuclease free water. Thermal cycler conditions were initial denaturation at 95°C for 10 minutes followed by 45 cycles of denaturation at 95°C for 15 s and annealing/extension at 60°C for 1 minute. The comparative ΔΔ Ct (cycle threshold) method was used for relative quantitation (RQ), where the amount of target genes ANRIL (Fig. 1A), aHIF (Fig. 1B), hPVT1 (Fig. 1C) are standardized to an endogenous reference gene (GAPDH) as a control. Melting curve analysis was applied for ANRIL (Fig. 1D), aHIF (Fig. 1E), hPVT1 (Fig. 1F) to specify target amplification and to exclude nonspecific amplicons and primer dimers.

Statistical analysis

Data were transferred to the computer and evaluated by means of IBM SPSS version 20.0. (Armonk, NY: IBM Corp.). The Kolmogorov-Smirnov test was performed to verify the normality of variables’ distribution. Receiver operating characteristic curve (ROC) analysis was applied to determine the diagnostic performance of the markers; area > 50% gives satisfactory performance and area about 100% is the best performance. Logistic regression analysis was applied to identify the most independent/affecting factor for influencing patients with HCC on top of chronic HBV and HCV infection. Significance of the obtained results was decided at the 5% level.

Results

This research was performed on 135 patients; they were 108 males (80%) and 27 females (20%) with age ranging from 35 to 75 years. Patients were grouped into 3 groups: group A comprised 45 HCC patients with chronic HCV infection, 34 (75.6%) males and 11 (24.4%) females with a mean age of 55.1 ±12.7; group B was composed of 40 patients with HCC related to chronic HBV infection, 36 (90%) males and 4 (10%) females with a mean age of 50.25 ±8.20; and group C included 50 patients with liver cirrhosis on top of chronic viral hepatitis; HCV or HBV, 38 (76%) males and 12 (24%) females with a mean age of 51.2 ±10.0. In addition, 47 apparently normal individuals with negative HBsAg and HCVAb and of matched age and gender formed a control group (group D) (Table 1).

Patients in all groups showed obviously lower count of hemoglobin (Hb), white blood cells (WBCs) and platelets (p < 0.001) vs. controls. The post hoc test for pairwise comparison between each two patient groups revealed that WBC count was clearly lower in group A and group C (p < 0.001) than group B while it did not differ between groups A and C (p = 0.705). In addition, WBC count did not differ between group B and controls (p = 0.173), though Hb and platelets did not significantly differ between patient groups (p > 0.05). Hepatic functions consisting of ALT, total bilirubin and international normalized ratio (INR) (p < 0.001) were predominantly higher in all patients than in controls whereas albumin (p < 0.001) was lower in patients than controls. Pairwise comparison between each two patient groups showed that ALT and albumin did not significantly differ between patient groups but total bilirubin was higher in group C than in group A (p = 0.03) and there was no significant difference between other patient groups and INR was significantly higher in group C than in group A (p = 0.007) and group B (p = 0.001) though it did not differ between groups A and B (p = 0.563). Erythrocyte sedimentation rate (ESR) either estimated at the first or the second hour was markedly higher in groups A and B (p < 0.001) than healthy participants, indicating presence of hepatic inflammation while there was no difference between groups C and D (p > 0.05). Moreover, ESR was higher in both groups A and B than in group C (p < 0.001) while it did not differ between groups A and B (p > 0.05) (Table 1).

Investigations of hepatic biomarkers revealed that two of the studied lncRNAs, namely ANRIL (Fig. 2A) and hPVT1 (Fig. 2C), were distinctly upregulated in all patients vs. controls (p < 0.001). Dunn’s test for multiple comparisons showed that both were elevated in groups A and B when compared with group C (p < 0.001) while they did not differ between groups A and B even though hPVT1 values were higher in the cirrhotic group than in controls but it did not reach a significant value (p = 0.703). Concerning aHIF, it was evidently downregulated in patients versus controls (p < 0.001) (Fig. 2B). Between groups, it was clearly lower in groups A and B than group C (p < 0.001) while not differing between the 2 HCC groups (p = 0.714) as well as between cirrhotic and control groups (p = 0.053). Also, the classic hepatic biomarker AFP was significantly higher in patients than in the control group (p < 0.001) (Fig. 2D); furthermore, it was elevated in groups A (p = 0.025) and B (p < 0.001) vs. group C though it did not differ between groups A and B (p = 0.055) (Table 1).

Clinical manifestations of the studied patients are presented in Table 2 where group B manifested the highest percentage of anorexia, 37 (92.5%) (p = 0.004), weight loss, 36 (90%) (p < 0.001) and cachexia, 26 (56%)
Table 1. Comparison between the four studied groups according to demographic data, laboratory investigation and lncRNAs markers

| Parameter                  | Group A (n = 45) | Group B (n = 40) | Group C (n = 50) | Group D (n = 47) | Test of sig. | p    |
|----------------------------|-----------------|-----------------|-----------------|-----------------|-------------|------|
| Gender, n (%)              |                 |                 |                 |                 |             |      |
| Male                       | 34 (75.6)       | 36 (90)         | 38 (76)         | 31 (66)         | χ² = 6.963  | 0.073|
| Female                     | 11 (24.4)       | 4 (10)          | 12 (24)         | 16 (34)         |             |      |
| Age (years)                |                 |                 |                 |                 | F = 2.397   | 0.070|
| Mean ±SD                   | 55.1 ± 12.7     | 50.25 ± 8.2     | 51.2 ± 10       | 50.7 ± 6.3      |             |      |
| Median (min.-max.)         | 55 (35-75)      | 49 (39-69)      | 50 (38-70)      | 51 (39-62)      |             |      |
| Hb (gm/dl)                 | 9.5± ±1.8       | 9.7± ±1.7       | 9.5± ±1.2       | 13.3± ±0.8      | F = 84.652  | < 0.001*|
| Median (min.-max.)         | 9.2 (6.5-13)    | 9.75 (7-13)     | 10 (5.8-10.8)   | 13 (12.6-15)    |             |      |
| WBCs (× 10³)               |                 |                 |                 |                 |             |      |
| Mean ±SD                   | 4.6 ±2.2        | 6 ±2.3          | 4.3 ±1.4        | 6.35 ±1.9       | K = 44.277  | < 0.001*|
| Median (min.-max.)         | 4² (2.1-11.2)   | 5.2² (3-11)     | 4² (2.5-9)      | 6² (4.5-10)     |             |      |
| PLT (× 10³)                |                 |                 |                 |                 |             |      |
| Mean ±SD                   | 132.5 ±49       | 138.95 ±51.9    | 136.7 ±60.7     | 295.6 ±83.4     | K = 90.311  | < 0.001*|
| Median (min.-max.)         | 139² (35-286)   | 149² (35-278)   | 119.5² (51-322) | 310² (174-438)  |             |      |
| ALT (IU/l)                 |                 |                 |                 |                 |             |      |
| Mean ±SD                   | 42.2 ± 14.6     | 46.7 ± 34.9     | 41 ± 16.1       | 28.8 ± 7.5      | K = 24.581  | < 0.001*|
| Median (min.-max.)         | 40² (25-77)     | 35² (18-150)    | 38.5² (18-90)   | 27² (17-40)     |             |      |
| Serum albumin (gm/dl)      |                 |                 |                 |                 |             |      |
| Mean ±SD                   | 3.2 ± 0.6       | 3.1 ± 0.6       | 3 ± 0.6         | 4.1 ± 0.4       | K = 89.589  | < 0.001*|
| Median (min.-max.)         | 3.4² (2-4.2)    | 3.3² (1.6-4)    | 3.1² (2.4-6)    | 4² (3.6-5)      |             |      |
| Total bilirubin (mg/dl)    |                 |                 |                 |                 |             |      |
| Mean ±SD                   | 2.3 ± 1.6       | 2.8 ± 2.6       | 2.8 ± 2         | 1 ± 0.1         | K = 67.729  | < 0.001*|
| Median (min.-max.)         | 1.3² (0.8 – 6)  | 1.35² (0.9 – 9.8) | 2.5² (1 – 13) | 1² (0.7 – 1.2) |             |      |
| INR                        |                 |                 |                 |                 |             |      |
| Mean ±SD                   | 1.4 ± 0.55      | 1.3 ± 0.4       | 1.5 ± 0.4       | 1 ± 0.1         | K = 68.644  | < 0.001*|
| Median (min.-max.)         | 1.2² (0.9-2.9)  | 1.1² (0.9-2.5)  | 1.4² (1.2-5)    | 1² (0.7-1)      |             |      |
| 1st ESR                    |                 |                 |                 |                 |             |      |
| Mean ±SD                   | 55.1 ± 34.4     | 60.9 ± 22.6     | 7.9 ± 3.35      | 5.9 ± 1.8       | K = 138.791 | < 0.001*|
| Median (min.-max.)         | 45² (16-120)    | 65² (18-100)    | 7² (3-15)       | 5² (3-9)        |             |      |
| 2nd ESR                    |                 |                 |                 |                 |             |      |
| Mean ±SD                   | 73.4 ± 34.1     | 93.8 ± 18.6     | 17 ± 6.7        | 13.45 ± 3.9     | K = 124.880 | < 0.001*|
| Median (min.-max.)         | 70² (13-130)    | 92.5² (55-120)  | 18² (7-30)      | 13² (7-21)      |             |      |
| ANRIL                      |                 |                 |                 |                 |             |      |
| Mean ±SD                   | 91.4 ± 130.8    | 52.3 ± 70.45    | 15.2 ± 62.2     | 1.8 ± 2.9       | K = 91.077  | < 0.001*|
| Median (min.-max.)         | 11.9² (1-519.1) | 32.1² (2-353.7) | 5.1² (0.02-444.4) | 0.2² (0.7-8) |             |      |
| aHIF                       |                 |                 |                 |                 |             |      |
| Mean ±SD                   | 3.7 ± 4.1       | 4.3 ± 5.4       | 15.8 ± 10.7     | 14.3 ± 17.2     | K = 58.424  | < 0.001*|
| Median (min.-max.)         | 1.4² (0.02-12.8) | 2.5² (0.3-19)   | 13.1² (0.02 – 55) | 7.0² (0.5 – 100.7) |             |      |
| hPVT1                      |                 |                 |                 |                 |             |      |
| Mean ±SD                   | 97 ± 96.6       | 96.92 ± 168.28  | 32.8 ± 150.6    | 4.6 ± 6.9       | K = 90.745  | < 0.001*|
| Median (min.-max.)         | 44.3² (10,2-353.1) | 26² (2.9-1001) | 1.4² (0.08-1067.3) | 3² (0.8-18.5) |             |      |
| AFP (ng/ml)                |                 |                 |                 |                 |             |      |
| Mean ±SD                   | 194.8 ± 654.4   | 338 ± 646       | 29.05 ± 24.8    | 1.3 ± 0.8       | K = 118.152 | < 0.001*|
| Median (min.-max.)         | 67² (5-4000)    | 86² (10-2730)   | 18² (2-81)      | 1² (0.5-4)      |             |      |

χ² – chi square test, F – F for ANOVA test, K – K for Kruskal-Wallis test
ALT – alanine aminotransferase, AST – aspartate aminotransferase, AFP – α-fetoprotein, Hb – hemoglobin concentration, WBCs – white blood cells, PLT – platelet count, INR – international normalized ratio, ANRIL – antisense non-coding RNA in the INK4 locus, aHIF – hypoxia-inducible factors, PVT1 – plasmacytoma variant translocation 1, p – p value for comparing between the studied groups, * statistically significant at p ≤ 0.05
Means/median with Common letters are not significant (i.e. means with different letters are significant)
Group A – patients with HCC on top of chronic HCV infection, Group B – patients with HCC on top of chronic HBV infection, Group C – patients with liver cirrhosis, Group D – healthy subjects as control
(p = 0.008). However, other findings including history of abdominal pain, GIT bleeding (hematemesis and/or melena), hepatic encephalopathy, jaundice, edema of lower limbs, local examination of liver, spleen and ascites, and Child score did not differ among patient groups (p > 0.05).

Table 2 presents the triphasic abdominal CT findings of the studied patients; group A presented the highest percentage of portal vein thrombosis 8 (17.8%) (p = 0.004). Hepatic focal lesions (number and size) did not differ between HCC patients in groups A and B (p > 0.05).

Spearman correlation of the hepatic biomarkers (ANRIL, aHIF, hPVT1 and AFP) with measured parameters in group A is shown in Table 3 where aHIF was positively related to platelets (r = 0.451, p = 0.002) and negatively related to maximum tumor size (r = –0.549, p < 0.001) though not related to each other or the remaining parameters. Correlations of biomarkers in group B displayed positive significant relations of aHIF with platelets (r = 0.420, p = 0.007), total bilirubin (r = 0.395, p = 0.012), INR (r = 0.673, p < 0.001), Child score (r = 0.336, p = 0.034) and a negative relation to maximum tumor size (r = –0.367, p = 0.02) while hPVT1 was negatively related to platelets (r = –0.363, p = 0.021), and positively related to total bilirubin (r = 0.336, p = 0.034) and maximum tumor size (r = 0.316, p = 0.047) (Table 4).

The ROC curve was indicative for ANRIL, aHIF, hPVT1 and AFP to discriminate group A (HCC on top of chronic HCV infection) patients from positive HCV RNA in cirrhotic patients of group C, where circulating aHIF could be the greatest diagnostic biomarker, whereas AUC 0.895 at cutoff ≤ 9.9 had the uppermost sensitivity 86.67% and specificity 91.89% followed by hPVT1 at AUC 0.881 and cutoff > 22.42 had sensitivity 77.78% and specificity 78.38%, then AFP had AUC.
Table 2. Comparison between the three studied groups according to clinical data and triphasic abdominal CT in patient groups

| Parameter                        | Group A (n = 45) | Group B (n = 40) | Group C (n = 50) | Test of sig. | p  |
|----------------------------------|------------------|------------------|------------------|--------------|----|
| Anorexia, n (%)                  | 31 (68.9)        | 37 (92.5)        | 31 (62)          | \( \chi^2 = 11.253 \) | 0.004* |
| Wight loss, n (%)                | 28 (62.2)        | 36 (90)          | 24 (48)          | \( \chi^2 = 17.534 \) | < 0.001* |
| Abd pain, n (%)                  | 14 (31.1)        | 10 (25)          | 8 (16)           | \( \chi^2 = 3.043 \) | 0.218 |
| GIT bleeding, n (%)              | 17 (37.8)        | 10 (25)          | 17 (34)          | \( \chi^2 = 1.645 \) | 0.439 |
| Encephalopathy, n (%)            | 12 (26.7)        | 10 (25)          | 11 (22)          | \( \chi^2 = 0.289 \) | 0.866 |
| Jaundice, n (%)                  | 20 (44.4)        | 14 (35)          | 29 (58)          | \( \chi^2 = 4.857 \) | 0.088 |
| Edema of both LL, n (%)          | 19 (42.2)        | 22 (55)          | 27 (54)          | \( \chi^2 = 1.802 \) | 0.406 |
| Cachexia, n (%)                  | 21 (46.7)        | 26 (65)          | 16 (32)          | \( \chi^2 = 9.723 \) | 0.008* |
| Local examination liver, n (%)   |                  |                  |                  | \( \chi^2 = 2.888 \) | 0.577 |
| Average size                     | 7 (15.6)         | 4 (10)           | 8 (16)           |              |    |
| Enshrunken                       | 30 (66.7)        | 31 (77.5)        | 38 (76)          |              |    |
| Enlarged                         | 8 (17.8)         | 5 (12.5)         | 4 (8)            |              |    |
| Local examination spleen, n (%)  |                  |                  |                  | \( \chi^2 = 8.567 \) | \(< p = 0.057 |
| No splenomegaly                  | 13 (28.9)        | 19 (47.5)        | 10 (20)          |              |    |
| Splenomegaly                     | 29 (64.4)        | 19 (47.5)        | 38 (76)          |              |    |
| Surgically removed               | 3 (6.7)          | 2 (5)            | 2 (4)            |              |    |
| Local examination ascites, n (%) |                  |                  |                  | \( \chi^2 = 5.206 \) | 0.267 |
| No                               | 34 (75.6)        | 30 (75)          | 33 (66)          |              |    |
| Mild to moderate                 | 3 (6.7)          | 6 (15)           | 11 (22)          |              |    |
| Massive                          | 8 (17.8)         | 4 (10)           | 6 (12)           |              |    |
| Child score, n (%)               |                  |                  |                  | \( \chi^2 = 2.796 \) | 0.593 |
| A                                | 23 (51.1)        | 22 (55)          | 20 (40)          |              |    |
| B                                | 14 (31.1)        | 12 (30)          | 17 (34)          |              |    |
| C                                | 8 (17.8)         | 6 (15)           | 13 (26)          |              |    |
| Median (min.-max.)               | 6 (5-13)         | 6 (5-13)         | 8 (5-12)         | \( K = 4.877 \) | 0.087 |
| Triphasic CT abdomen             |                  |                  |                  |              |    |
| Liver FL number, n (%)           |                  |                  |                  |              |    |
| Single                           | 30 (66.7)        | 22 (55)          | –                | \( \chi^2 = 1.214 \) | 0.271 |
| Multiple                         | 15 (33.3)        | 18 (45)          | –                |              |    |
| Max. size of FL                  |                  |                  |                  | \( U = 883.0 \) | 0.880 |
| Mean ±SD                         | 4.4 ±3.4         | 4.1 ±2.25        | –                |              |    |
| Median (min.-max.)               | 3 (1.5-14)       | 3.4 (2.1-12)     | –                |              |    |
| Portal vein size, n (%)          |                  |                  |                  | \( \chi^2 = 1.948 \) | 0.378 |
| Not dilated                      | 14 (31.1)        | 18 (45)          | 17 (34)          |              |    |
| Dilated                          | 31 (68.9)        | 22 (55)          | 33 (66)          |              |    |
| Portal vein patency, n (%)       |                  |                  |                  | \( \chi^2 = 10.371 \) | \(< p = 0.004* |
| Patent                           | 37 (82.2)        | 36 (90)          | 50 (100)         |              |    |
| Thrombosis                       | 8 (17.8)         | 4 (10)           | 0 (0)            |              |    |

\( \chi^2 \) – chi square test, MC – Monte Carlo, K – K for Kruskal-Wallis test, U – Mann-Whitney U test

p – p value for comparing between the studied groups, *statistically significant at p ≤ 0.05

Group A – patients with HCC on top of chronic HCV infection, Group B – patients with HCC on top of chronic HBV infection, Group C – patients with liver cirrhosis
0.709 at cutoff > 21 had sensitivity 71.11% and specificity 70.27%, and finally ANRIL had AUC 0.720 at cutoff > 11.01 and had the lowest sensitivity (60.0%) and specificity (67.57%) (Table 5, Fig. 3A). Moreover, combination of AFP with each lncRNA biomarker of (ANRIL, aHIF and hPVT1) revealed a rise of both sensitivity (91.11%) and specificity (83.78%) of aHIF with AUC 0.930 and also hPVT1 had sensitivity 95.56% and specificity 70.27% with AUC 0.903 and for ANRIL sensitivity was 77.78% and specificity 72.97% at AUC 0.787 (Fig. 3C); these results could indicate that combinations of aHIF and AFP could be better used for diagnosis of HCC on top of HCV owing to improvement of both sensitivity and specificity by combination.

Whereas the ROC curve for ANRIL, aHIF, hPVT1 and AFP to distinguish group B (HCC on top of HBV) patients from positive HBV RNA in cirrhotic patients of group C, where circulating hPVT1 could be the supreme diagnostic biomarker, whereas AUC was 0.823 at cutoff > 7.5, it had sensitivity 85.0% and specific-

Table 3. Correlation between markers (ANRIL, aHIF, hPVT1 and AFP) with different parameters in group A (patients with HCC on top of chronic HCV infection) (n = 45)

| Parameter | ANRIL | aHIF | hPVT1 | AFP |
|-----------|-------|------|-------|-----|
| r_s       | p     | r_s  | p     | r_s |
| ANRIL     | 1.000 | -0.249 0.099 | 0.150 0.324 -0.072 0.637 | -0.092 0.546 -0.091 0.553 0.027 0.861 |
| aHIF      |       | -0.249 0.099 |       |       |
| hPVT1     | 0.150 0.324 -0.072 0.637 |       |       |
| AFP       | -0.092 0.546 -0.091 0.553 0.027 0.861 |       |       |
| Age (years) |       |       |       |       |
| PLT       | -0.241 0.111 0.451 0.002 -0.091 0.552 0.129 0.397 |       |       |
| ALT       | 0.285 0.058 0.201 0.187 0.033 0.831 0.147 0.336 |       |       |
| Serum albumin | 0.086 0.574 -0.052 0.736 0.001 0.995 -0.085 0.577 |       |       |
| Bilirubin total | 0.177 0.245 0.129 0.400 0.046 0.765 -0.013 0.934 |       |       |
| INR       | -0.065 0.674 0.173 0.254 -0.008 0.957 0.026 0.867 |       |       |
| Child score | 0.018 0.904 0.197 0.194 -0.041 0.791 -0.072 0.637 |       |       |
| Tumor size (CT) | 0.180 0.238 -0.549 < 0.001 0.059 0.701 0.044 0.773 |       |       |

rs – Spearman coefficient, *statistically significant at p ≤ 0.05
ANRIL – antisense non-coding RNA in the INK4 locus, aHIF – hypoxia-inducible factors, PVT1 – plasmacytoma variant translocation 1, AFP – α-fetoprotein, ALT – alanine aminotransferase, PLT – platelet count, INR – international normalized ratio

Table 4. Correlation between markers with different parameters in group B (patients with HCC on top of chronic HBV infection) (n = 40)

| Parameter | ANRIL | aHIF | hPVT1 | AFP |
|-----------|-------|------|-------|-----|
| r_s       | p     | r_s  | p     | r_s |
| ANRIL     | 1.000 | 0.046 0.779 |       |       |
| aHIF      |       | 0.046 0.779 |       |       |
| hPVT1     | 0.044 0.785 |       |       |
| AFP       | -0.207 0.200 0.121 0.459 |       |       |
| Age (years) |       |       |       |       |
| PLT       | -0.308 0.053 0.420 0.007 -0.363 0.021 |       |       |
| ALT       | 0.265 0.098 |       |       |
| Serum albumin | -0.034 0.835 -0.278 0.083 -0.298 0.062 |       |       |
| Bilirubin total | 0.085 0.604 0.395 0.012 0.336 0.034 |       |       |
| INR       | -0.036 0.823 0.673 | < 0.001 0.233 |       |       |
| Child score | 0.058 0.724 0.336 0.034 |       |       |
| Max. size CT | 0.109 0.505 -0.367 |       |       |

rs – Spearman coefficient, *statistically significant at p ≤ 0.05
ANRIL – antisense non-coding RNA in the INK4 locus, aHIF – hypoxia-inducible factors, PVT1 – plasmacytoma variant translocation 1, AFP – α-fetoprotein, ALT – alanine aminotransferase, PLT – platelet count, INR – international normalized ratio
Table 5. Agreement (sensitivity, specificity) for ANRIL, aHIF, hPVT1 and AFP to diagnose group A (patients with HCC on top of chronic HCV infection) (n = 45) from positive HCV RNA in group C (patients with liver cirrhosis) (n = 37)

| Parameter | AUC   | p     | 95% CI          | Cut off | Sensitivity | Specificity | PPV  | NPV  |
|-----------|-------|-------|-----------------|---------|-------------|-------------|------|------|
| ANRIL     | 0.720 | < 0.001*  | 0.609–0.830      | > 11.01 | 60.0        | 67.57       | 69.2 | 58.1 |
| aHIF      | 0.895 | < 0.001*  | 0.811–0.980      | < 9.9† | 86.67       | 91.89       | 92.9 | 85.0 |
| hPVT1     | 0.881 | < 0.001*  | 0.804–0.959      | > 22.42 | 77.78       | 78.38       | 81.4 | 74.4 |
| AFP       | 0.709 | < 0.001*  | 0.595–0.823      | > 21   | 71.11       | 70.27       | 74.4 | 66.7 |

AUC – area under a curve, p value – probability value, CI – confidence intervals, NPV – negative predictive value, PPV – positive predictive value
*statistically significant at p < 0.05, †cut-off was choose according to Youden index
ANRIL – antisense non-coding RNA in the INK4 locus, aHIF – hypoxia-inducible factor, PVT1 – plasmacytoma variant translocation 1, AFP – α-fetoprotein

Fig. 3. A) ROC curve for ANRIL, aHIF, hPVT1 and AFP to diagnose patients with HCC on top of chronic HCV infection from patients with liver cirrhosis, B) ROC curve for ANRIL, aHIF, hPVT1 and AFP to diagnose patients with HCC on top of chronic HBV infection from patients with liver cirrhosis, C) ROC curve for combination for AFP with each biomarker of ANRIL, aHIF and hPVT1 to diagnose patients with HCC on top of chronic HCV from patients with liver cirrhosis, D) ROC curve for combination for AFP with each biomarker of ANRIL, aHIF and hPVT1 to diagnose patients with HCC on top of chronic HBV infection (n = 40) from patients with liver cirrhosis.
Table 6. Agreement (sensitivity, specificity) for ANRIL, aHIF, hPVT1 and AFP to diagnose group B (patients with HCC on top of chronic HBV infection) \((n = 40)\) from positive HBV DNA in group C (patients with liver cirrhosis) \((n = 13)\)

| Parameter | AUC | \(p\) | 95\% CI | Cut off | Sensitivity | Specificity | PPV | NPV |
|-----------|-----|------|--------|--------|------------|------------|------|-----|
| ANRIL     | 0.902 | < 0.001* | 0.821-0.983 | > 11.97 | 82.50 | 92.31 | 97.1 | 63.2 |
| aHIF      | 0.798 | 0.001* | 0.618-0.978 | < 5.1 | 80.0 | 76.92 | 91.4 | 55.6 |
| hPVT1     | 0.823 | 0.001* | 0.663-0.983 | > 7.5 | 85.0 | 84.62 | 94.4 | 64.7 |
| AFP       | 0.742 | 0.009* | 0.607-0.878 | > 60 | 62.50 | 53.85 | 80.6 | 31.8 |

AUC – area under a curve, \(p\) value – probability value, CI – confidence intervals, NPV – negative predictive value, PPV – positive predictive value.

*statistically significant at \(p \leq 0.05\), ^*cut-off was chosen according to Youden index.

ANRIL – antisense non-coding RNA in the INK4 locus, aHIF – hypoxia-inducible factors, PVT1 – plasmacytoma variant translocation 1, AFP – α-fetoprotein.

Table 7. Univariate and multivariate logistic regression analysis for the parameters affecting group A (patients with HCC on top of chronic HCV infection) \((n = 45)\) vs. positive HCV RNA \((\times 10^5)\) in group C (patients with liver cirrhosis) \((n = 37)\)

| Parameter | Univariate | Multivariate |
|-----------|------------|--------------|
|           | \(p\) | OR (95\% CI) | \(p\) | OR (95\% CI) |
| Female    | 0.990 | 1.007 (0.365-2.772) | 0.962 | 1.089 (0.033-36.349) |
| Age       | 0.158 | 1.028 (0.989-1.068) | 0.185 | 0.581 (0.260-1.297) |
| General examination of Jaundice | 0.038 | 2.604 (1.053-6.439) | 0.991 | 0.981 (0.043-22.557) |
| Hepatic encephalopathy | 0.040 | 4.121 (1.065-15.941) | 0.139 | 0.438 (0.147-1.308) |
| Hb        | 0.791 | 1.038 (0.788-1.367) | 0.185 | 0.581 (0.260-1.297) |
| PLT       | 0.305 | 1.005 (0.995-1.015) | 0.185 | 0.581 (0.260-1.297) |
| Child score | 0.031 | 0.818 (0.681-0.981) | 0.185 | 0.581 (0.260-1.297) |
| 1st ESR   | 0.049 | – | – | – |
| Portal vein thrombosis CT | 0.099 | – | – | – |
| ANRIL     | < 0.001 | 3.499 (1.751-6.992) | 0.021 | 4.183 (1.238-14.138) |
| aHIF      | 0.001 | 0.200 (0.079-0.503) | 0.139 | 0.438 (0.147-1.308) |
| hPVT1     | < 0.001 | 14.187 (4.230-47.577) | 0.001 | 29.682 (3.862-228.135) |
| AFP       | 0.001 | 5.445 (1.932-15.343) | 0.060 | 6.744 (0.921-49.370) |

OR – odds ratio, CI – confidence interval, LL – lower limit, UL – upper limit.

#All variables with \(p < 0.05\) were included in the multivariate analysis, *statistically significant at \(p < 0.05\)
Univariate and multivariate analysis for the factors identifying HCC patients on top of HBV vs. patients with liver cirrhosis related to HBV revealed that with the univariate test, ANRIL \( p = 0.001 \), OR = 15.70 (3.163-77.945), \( aHIF \) \( p = 0.03 \), OR = 0.263 (0.079-0.877), \( hPVT1 \) \( p = 0.003 \), OR = 4.527 (1.662-12.335) and AFP \( p = 0.016 \), OR = 4.429 (1.314-14.924) could be meaningful in disease prediction, whereas in multivariate analysis ANRIL \( p = 0.031 \), OR = 12.307 (1.263-119.883), \( aHIF \) \( p = 0.049 \), OR = 0.246 (0.061-0.996), \( hPVT1 \) \( p = 0.047 \), OR = 3.617 (1.020-12.828) could be independent predictors of HCC on top of HBV infection (Table 8).

**Discussion**

Hepatocellular carcinoma is deemed to be the most common primary liver malignancy and globally represents a principal cause of cancer-linked mortality [16].

As most HCC patients are diagnosed late with underlying liver dysfunction, the mortality rate of such patients is analogous to the incidence rate. In addition, HCC is still one of the cancers with a worse prognosis; consequently to ameliorate survival in these patients, early detection of HCC is quite important. For patients at risk for HCC progression, the use of reliable biological markers can help in reduction of medical costs as well as lowering HCC mortality [17].

\( \alpha \)-fetoprotein has been the habitually utilized biomarker for HCC diagnosis, but its clinical value is challenged because of its low specificity and sensitivity [18, 19]. In addition, AFP levels remain normal in 15-30% of advanced stage HCC patients, and may rise in some chronic hepatitis, liver cirrhosis, and other liver disease patients, resulting in high false negative and false-positive rates [20]. Consequently, for screening and more accurate HCC diagnosis novel markers complementing the limitations of AFP are deemed necessary. We dedicated this study to investigating three important IncRNAs that have been recently linked to liver diseases, i.e. ANRIL, \( aHIF \) and \( hPVT1 \), and we strikingly displayed noteworthy outcomes counting upregulation of ANRIL and \( hPVT1 \) and downregulation of \( aHIF \) in patients with HCC on top of HCV and HBV compared with healthy participants. Moreover, cirrhotic patients had higher ANRIL levels than healthy participants although \( aHIF \) and \( hPVT1 \) levels did not differ between them.

These results were in accordance with previous literature, where IncRNA ANRIL might act as a prospective curative goal as its expression is augmented in HCC tissues and intensely interrelated with progressive clinical features, and the diminishing ANRIL expression might repress HCC cell expansion, relocation and infiltration [21]. An additional report suggested that ANRIL overexpression might be a key issue for HCC progression, over quieting of Kruppel-like factor 2 (KLF2) by binding with PRC2 [22].

---

**Table 8.** Univariate and multivariate logistic regression analysis for the parameters affecting group B (patients with HCC on top of chronic HBV infection) \( (n = 40) \) vs. negative HCV RNA \( \times 10^5 \) in group C (patients with liver cirrhosis) \( (n = 13) \)

| Parameter                  | Univariate | Multivariate |
|----------------------------|------------|--------------|
| Male                       | 0.239      | 2.700 (0.517-14.098) |
| Age                        | 0.937      | 0.997 (0.925-1.074)  |
| General examination of jaundice | 0.958     | 0.964 (0.248-3.750)  |
| Hepatic encephalopathy     | 0.638      | 1.714 (0.182-16.182) |
| Hb                         | 0.707      | 0.923 (0.609-1.400)  |
| PLT                        | 0.055      | 0.990 (0.980-1.000)  |
| Child score                | 0.478      | 1.119 (0.820-1.527)  |
| 1st ESR                    | 0.987      | -             |
| Portal vein thrombosis CT  | 0.999      | -             |
| ANRIL                      | 0.001*     | 15.700 (3.163-77.945) |
| \( aHIF \)                 | 0.030*     | 0.263 (0.079-0.877)  |
| \( hPVT1 \)                | 0.003*     | 4.527 (1.662-12.335) |
| AFP                        | 0.016*     | 4.429 (1.314-14.924) |

OR – odds ratio, CI – confidence interval, LL – lower limit, UL – upper limit

\*All variables with \( p < 0.05 \) were included in the multivariate analysis, \*statistically significant at \( p < 0.05 \)
Zhang et al. [23] reported that ANRIL levels were elevated both in cirrhosis vs. normal liver and in HCC vs. cirrhosis, signifying its contribution during hepatocarcinogenesis from normal liver over the precancerous stage of cirrhosis. It is observed that ANRIL acts in HCC progression through p15/CDKN2A in *cis* and in *trans* through heterochromatin establishment or DNA methylation, since the p15 promoter is often methylated in tumor tissues from HCC patients [24].

A previous report on circulating IncRNA in HCC stated that hPVT1 and uc002mbe.2 were upregulated and together served as a precise diagnostic biomarker [25]. Human hPVT1 is enhanced in HCC tissues and is allied with poor prospects, augmented cellular spread and migration that is attained by attaching and stabilizing a cell cycle gene (NOP2), through switch spread and migration that is attained by attaching and stabilizing a cell cycle gene (NOP2), through switch.

Guo et al. [28] confirmed that hPVT1 was elevated in HCC, and inhibition of hPVT1 repressed cell expansion and stimulated apoptosis. They in addition added that PVT1 might increase EZH2 protein stability. For the meantime, hPVT1 boosted EZH2 and MDM2 protein expression along with hindering P53 expression in HCC cells.

aHIF (IncRNA antisense to HIF1A) has been deregulated in numerous cancer types, including HCC [29]. aHIF is depressed in HCC and an original explanation was that HOTAIR might repress HIF1A expression by competitively sponging miR-130a-3p in HCC cells. Moreover, knockdown of HOTAIR could diminish HCC cell viability under hypoxia by controlling miR-130a-3p and HIF1A, signifying that the network of HOTAIR/miR-130a-3p/HIF1A could provoke HCC evolution [30].

Operative tools of IncRNAs in HCC comprise DNA binding, RNA interaction, protein connections, and creating small peptides. Initially, joining to DNA permits IncRNAs to alter chromatin structure and epigenetic variations, thus adjusting the target genes’ expression. Then, IncRNAs cooperate with miRNAs or miRNAs as a molecular sponge, thus moderating the miRNAs’ stability and translation. In addition, IncRNAs can efficiently connect with proteins to adjust their conformation, localization or stability. Also, a part of IncRNAs hold small open reading frames (sORFs) that code peptides with biological tasks [31].

We observed remarkable associations between aHIF and platelets, maximum tumor size in HCC on top of HCV and association of aHIF with platelets, total bilirubin, INR, Child score and maximum tumor size while hPVT1 was related to platelets, total bilirubin, and maximum tumor size in HCC on top of HBV.

Yu et al. [25] stated that a major association was noted between hPVT1 and tumor size, Barcelona-Clinic Liver Cancer Classification (BCLC) stage, and the serum bilirubin level. Furthermore, Wang et al. [26] conducted Kaplan-Meier analysis of 89 HCC patients and identified that elevated hPVT1 levels in HCC tissues were appreciably related to evidently lower recurrence free survival (RFS) and overall survival (OS) in HCC patients and that high hPVT1 levels were linked to larger tumor size, HBV infection, and tumor staging but not metastasis phenotype.

Our results indicate that circulating aHIF could be the greatest diagnostic biomarker for differentiating HCC on top of HCV from cirrhotic patients and furthermore aHIF and AFP combination enhances diagnosis accuracy whereas circulating hPVT1 could be the top diagnostic biomarker for discriminating HCC on top of HBV from cirrhotic patients due to having the highest sensitivity and specificity, and this might explain why IncRNAs behave differently in HCC depending on viral etiology.

Zhang et al. [23] supports this conclusion that aHIF was predominately downregulated in HCV-related HCC and that hPVT1 was notably increased only in HBV-related HCC, not in HCV- and HDV-related HCC.

Yu et al. [25] reported that PVT1 and uc002mbe.2 had a predictive ability superior to AFP with AUC 0.764, sensitivity 60.56% and specificity 90.62%. A preceding study also stated that hPVT1 was increased via the TGF-β route, which can be triggered by HBV infection in HBV-linked HCC tissues [32].

HIF-1 works as an antiapoptotic factor. In the study by Xia and coworkers, it was elucidated that Forkhead box M1 (FoxM1) performs as a proliferation-specific transcription factor in HCC cell progression and HIF-1 straightforwardly binds to the FoxM1 promoter induced by tumor necrosis factor α (TNF-α), which suggests that the TNF-α/HIF-1 prompted increase of FoxM1 levels that stimulated the spread of hepatoma cells and their resistance to apoptosis [33].

An ongoing study discovered that ANRIL expression was predominately elevated in HCC tissues competed with the healthy adjacent tissues and experimentally indicated that ANRIL overexpression provoked mitochondrial function in HCC cells, evident by the augmenting mitochondrial DNA copy numbers, ATP level, mitochondrial membrane potential, and the levels of mitochondrial markers, whereas ANRIL knockdown had opposite effects [34].

Recently, Jiang and his coworkers detected that IncRNA hPVT1 was upregulated and stimulated HBV liv-
er cancer progression by disturbing histone methylation on the MYC promoter, proposing that hPVT1 may be a possible target for mounting diagnostic and curative plans of HBV liver cancer at the initial stages [35].

**Conclusions**

Molecular signatures using lncRNA expression have been displayed as a prospective predictive biomarker of HCC. In association with AFP (the currently classic HCC biomarker), the differential expression of lncRNAs (ANRIL, aHIF and hPVT1) can be used in advance to improve the accuracy of early diagnosis of HCC and could provide early therapeutic tools in HCC management and so better prognosis.

Consent to participate: Written informed consent was obtained from all participants.

**Disclosure**

The authors declare no conflict of interest.

**References**

1. Ziogas IA, Tsoulfas G. Advances and challenges in laparoscopic surgery in the management of hepatocellular carcinoma. World J Gastrointest Surg 2017; 9: 233-245.
2. Zhang Y, Huang JC, Kai KT, et al. Long non-coding RNA HOTTIP promotes hepatocellular carcinoma tumorigenesis and development: A comprehensive investigation based on bioinformatics, qRT-PCR and meta-analysis of 393 cases. Int J Oncol 2017; 51: 1705-1721.
3. Zhang X, Tang W, Chen G, et al. An encapsulation of gene signatures for hepatocellular carcinoma, microRNA-132 predicted target genes and the corresponding overlaps. PLoS One 2016; 11: 1594-1598.
4. Hashimoto K, Suzuki AM, Dos Santos A, et al. CAGE profiling of ncRNAs in hepatocellular carcinoma reveals widespread activation of retroviral LTR promoters in virus-induced tumors. Genome Res 2015; 25: 1812-1824.
5. Jing W, Gao S, Zhu M, et al. Potential diagnostic value of lncRNA SPRY4-IT1 in hepatocellular carcinoma. Oncol Rep 2016, 36: 1085-1092.
6. Albrecht AS, Ørom UA. Bidirectional expression of long ncRNA/protein-coding gene pairs in cancer. Brief Funct Genomics 2016; 15: 167-173.
7. Zhang SW, Fan XN. Computational methods for predicting ncRNA-protein interactions. Med Chen 2017; 13: 515-525.
8. Mishra A, Bohra A. Non-coding RNAs and plant male sterility: current knowledge and future prospects. Plant Cell Rep 2018; 37: 177-191.
9. Yang I, Lyu I, Wu W, et al. Genome-wide identification of long non-coding RNA and mRNA profiling using RNA sequencing in subjects with sensitive skin. Oncotarget 2017; 8: 114894-114910.
10. Qu S, Liu Z, Yang X, et al. The emerging functions and roles of circular RNAs in cancer. Cancer Lett 2018; 414: 301-309.
11. Mckeown SR. Defining normoxia, physioxia and hypoxia in tumours-implications for treatment response. Br J Radiol 2014; 87: 201.
12. Dengler VL, Galbraith MD, Espinosa JM. Transcriptional regulation by hypoxia inducible factors. Crit Rev Biochem Mol Biol 2014; 49: 1-15.
13. Kong R, Zhang EB, Yin DD, et al. Long non-coding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16. Mol Cancer 2015; 14: 82.
14. Zenin A, Tsepliyov Y, Sharapov S, et al. Identification of 12 genetic loci associated with human healthspan. Commun Biol 2019; 2: 41.
15. Kotake Y, Nakagawa T, Kitagawa K, et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene 2011; 30: 1956-1962.
16. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391: 1301-1314.
17. Khalaf N, Ying J, Mittal S, et al. Natural history of untreated hepatocellular carcinoma in a US cohort and the role of cancer surveillance. Clin Gastroenterol Hepatol 2017; 15: 273-281.
18. Jang ES, Jeong SH, Kim JW, et al. Diagnostic performance of alpha-fetoprotein, protein induced by vitamin K absence, Osteopontin, Dickkopf-1 and its combinations for hepatocellular carcinoma. PLoS One 2016; 11: e0151069.
19. Soliman SE, EITorgoman AMA, Assar MFA, et al. Biochemical and molecular study of long non-coding RNAs (HOTTIP, ZEB-AS1 and MEG-3) in hepatocellular carcinoma. Meta Gene 2020; 26: 100808.
20. Jing W, Luo P, Zhu M, et al. Prognostic and diagnostic significance of SDPR-Cavin-2 in hepatocellular carcinoma. Cell Physiol Biochem 2016; 39: 950-960.
21. Hua L, Wang CY, Yao KH, et al. High expression of long non-coding RNA ANRIL is associated with poor prognosis in hepatocellular carcinoma. Int J Clin Exp Pathol 2015; 8: 3076-3082.
22. Huang MD, Shen WM, Qi FZ, et al. Long non-coding RNA ANRIL is upregulated in hepatocellular carcinoma and regulates cell apoptosis by epigenetic silencing of KLF2. J Hematol Oncol 2015; 8: 57.
23. Zhang Q, Matsuura K, Kleiner DE, et al. Analysis of long non-coding RNA expression in hepatocellular carcinoma reveals widespread activation of retroviral LTR promoters in virus-induced tumors. Genome Res 2015; 25: 1812-1824.
24. Wang F, Yuan JH, Wang SB, et al. Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells. Cancer Tumor Biol 2016; 95: e4436.
25. Wang F, Yuan JH, Wang SB, et al. Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2. Mol Biochem 2016; 39: 1278-1290.
26. Tan L, Yan X, Li Z, et al. Long non-coding RNA PVT1 serves as a competing endogenous RNA for miR-186-5p to promote the tumorigenesis and metastasis of hepatocellular carcinoma. Tumour Biol 2017; 39: 1010428317705338.
27. Guo J, Hao C, Wang C, et al. Long non-coding RNA PVT1 modulates hepatocellular carcinoma cell proliferation and apoptosis by recruiting EZH2. Cancer Cell Int 2018; 18: 98.
29. Unfried JP, Fortes P. LncRNAs in HCV infection and HCV-related liver disease. Int J Mol Sci 2020; 21: 2255.
30. Hu M, Fu Q, Jing C, Zhang X, Qin T, Pan Y. LncRNA HOTAIR knockdown inhibits glycolysis by regulating miR-130a-3p/HIF1A in hepatocellular carcinoma under hypoxia. Biomed Pharmacother 2020; 125: 109703.
31. Huang Z, Zhou JK, Peng Y, et al. The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer 2020; 19: 77.
32. Yang P, Li QJ, Feng Y, et al. TGF-beta-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular cancer. Cell 2012; 22: 291-303.
33. Xia L, Mo P, Huang W, et al. The TNF-α/ROS/HIF-1-induced upregulation of FoxM1 expression promotes HCC proliferation and resistance to apoptosis. Carcinogenesis 2012; 33: 2250-2259.
34. Li K, Zhao B, Wei D, et al. Long non-coding RNA ANRIL enhances mitochondrial function of hepatocellular carcinoma by regulating the MiR-199a-5p/ARL2 axis. Environ Toxicol 2020; 35: 313-321.
35. Jiang B, Yang B, Wang Q, et al. LncRNA PVT1 promotes hepatitis B virus-positive liver cancer progression by disturbing histone methylation on the c-Myc promoter. Oncol Rep 2020; 43: 718-726.